Bahrain’s health ministry approves emergency use of COVID-19 medication Sotrovimab

Published: Updated:
Enable Read mode
100% Font Size

Bahrain’s Ministry of Health has approved the emergency use of the COVID-19 medication Sotrovimab, according to a statement issued on Thursday.

For more coronavirus news, visit our dedicated page.


“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalization, the health ministry said.

According to the ministry, safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalization for more than 24 hours and a reduction in the number of fatalities by 85 percent, when administered at an early stage of treatment.

Earlier this month, Bahrain approved the emergency use for regn-cov2 medicine, Regeneron Pharmaceuticals Inc’s and Roche’s newly authorized COVID-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms.

Read more:

Bahrain approves emergency use for Regeneron COVID-19 medicine: BNA

Bahrain extends support program for businesses hit by COVID-19 pandemic

Bahrain says Sputnik V vaccine demonstrates 94.3 pct efficacy, ‘high safety profile’

Top Content Trending